Table 3.
Drugs that alter the ratio of full length to skipped SMN2 transcripts
| Drug | Drug type | Effect on SMN2 Transcription | Animal tested | Drug Trial | Selected Citations |
|---|---|---|---|---|---|
| 5-(N-ethyl-N-isopropyl)-amiloride (EIPA) | Na+/H+ exchange inhibitor | Not evaluated | No | No | 72 |
| Aclarubicin | Anthracycline antibiotic | Increased | No | No | 66, 67 |
| Curcumin | Polyphenol | Not evaluated | No | No | 71 |
| Epigallocatechin galate (EGCG) | Polyphenol | Not evaluated | No | No | 71 |
| Hydroxyurea (HU) | ribonucleotide reductase inhibitor | No increase in SMN2 transcripts | Yes | Yes | 65, 76, 84 |
| LBH589 | Hydroxamic acid derived HDAC inhibitor | Increased | Yes | No | 63 |
| M344 | Benzamide, HDAC inhibitor | Increased | No | No | 64 |
| Phenylbutyrate (PB) | Aromatic fatty acid, HDAC inhibitor | Increased | No | Yes | 57, 77, 78, 79 |
| PTK-SMA1 | Tetracycline derivative | N/A | Yes | No | 70 |
| Resveratrol | Polyphenol | Not evaluated | No | No | 71 |
| Salbutamol | Beta2-adrenoceptor agonist | Increased | No | Yes | 69, 85 |
| Sodium butyrate (SB) | HDAC inhibitor | Increased SMN2 promoter activity | Yes | No | 60, 62 |
| Sodium vanadate | Protein phosphatase inhibitor | Increased | No | No | 67, 68 |
| Suberoylanilide hydroxamic acid (SAHA) | HDAC inhibitor | Increased | No | No | 61 |
| Trichostatin A (TSA) | HDAC inhibitor | Increased SMN2 promoter activity | Yes | No | 60, 74, 75 |
| Valproic acid (VPA) | Branched chain fatty acid, HDAC inhibitor | Increased | Yes | Yes | 58, 59, 73, 80, 81, 82, 83 |